Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
28720439
DOI
10.1016/j.clgc.2017.06.006
PII: S1558-7673(17)30185-4
Knihovny.cz E-resources
- Keywords
- Pazopanib, Renal cell carcinoma, Sorafenib, Sunitinib, Survival,
- MeSH
- Survival Analysis MeSH
- Bevacizumab therapeutic use MeSH
- Molecular Targeted Therapy MeSH
- Adult MeSH
- Phenylurea Compounds therapeutic use MeSH
- Indazoles MeSH
- Indoles therapeutic use MeSH
- Angiogenesis Inhibitors therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Kidney Neoplasms drug therapy MeSH
- Niacinamide analogs & derivatives therapeutic use MeSH
- Disease-Free Survival MeSH
- Pyrimidines therapeutic use MeSH
- Pyrroles therapeutic use MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sorafenib MeSH
- Sulfonamides therapeutic use MeSH
- Sunitinib MeSH
- Vascular Endothelial Growth Factor A antagonists & inhibitors MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Bevacizumab MeSH
- Phenylurea Compounds MeSH
- Indazoles MeSH
- Indoles MeSH
- Angiogenesis Inhibitors MeSH
- Niacinamide MeSH
- pazopanib MeSH Browser
- Pyrimidines MeSH
- Pyrroles MeSH
- Sorafenib MeSH
- Sulfonamides MeSH
- Sunitinib MeSH
- Vascular Endothelial Growth Factor A MeSH
- VEGFA protein, human MeSH Browser
BACKGROUND: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. PATIENTS AND METHODS: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. RESULTS: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference < .001 and .009 for OS difference). CONCLUSION: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years.
Department of Oncology University Hospital Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
University Hospital in Hradec Kralove Hradec Kralove Czech Republic
References provided by Crossref.org
